Back to Home
Featured

Optimizing Care for Patients With Triple-Negative Breast Cancer Through Pharmacist Interventions in Supportive Care and Toxicity Management

August 4, 2022 | 6:00 & 8:00 PM ET

This activity includes patient counseling video vignettes.

This activity is part 3 of a 5-part webinar series

Program Description

Pharmacists have important roles in ensuring medication adherence and providing supportive care management to patients with triple-negative breast cancer (TNBC). This module will review strategies for pharmacists to optimize and personalize management of patients with TNBC. Specific toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates will be discussed, with a focus on the pharmacist’s role in monitoring for and mitigating adverse effects of therapy. In addition, counseling points regarding medication administration, potential drug interactions, and barriers to adherence will be covered to assist pharmacists in providing individualized supportive care for patients with TNBC. Counseling videos incorporated throughout this activity will provide pharmacists with key pearls to provide when educating patients with TNBC about treatment expectations, adverse effect management, and provision of supportive care.


Target audience: Health-system pharmacists, managed care pharmacists, oncology pharmacists, specialty pharmacists

Type of activity: Application
Release date: August 4, 2022
Expiration date: October 4, 2022

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Identify the role of the pharmacist in the provision of supportive care for patients with triple-negative breast cancer (TNBC)
  • Analyze the toxicities specific to novel agents such as poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates for the treatment of TNBC
  • Develop a plan to effectively mitigate, monitor, or treat toxicities associated with novel drug therapies for the treatment of TNBC

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

What's Included
  • Access your activities anytime, anywhere, with a computer, tablet or smartphone
  • Free access with a PTCE account
  • Pharmacy education designed to improve patient care

Related Content